Rocket Pharmaceuticals withdraws BLA for gene therapy RP-L102 in the US
NegativeFinancial Markets

Rocket Pharmaceuticals has decided to withdraw its Biologics License Application (BLA) for the gene therapy RP-L102 in the United States. This move is significant as it reflects challenges in the regulatory approval process for innovative treatments. The withdrawal may impact patients awaiting this therapy and raises questions about the future of gene therapy developments in the country.
— Curated by the World Pulse Now AI Editorial System